Unique ID issued by UMIN | UMIN000025905 |
---|---|
Receipt number | R000029337 |
Scientific Title | Multicenter study of Genome-Wide Association Study (GWAS) concerning of the efficacy of tolvaptan. |
Date of disclosure of the study information | 2017/02/01 |
Last modified on | 2020/02/18 15:00:33 |
Multicenter study of Genome-Wide Association Study (GWAS) concerning of the efficacy of tolvaptan.
Effect of tolvaptan on refractory ascites.
Multicenter study of Genome-Wide Association Study (GWAS) concerning of the efficacy of tolvaptan.
Effect of tolvaptan on refractory ascites.
Japan |
Liver cirrhosis with refractory ascites.
Medicine in general | Hepato-biliary-pancreatic medicine |
Others
YES
To elucidate the gene concerning for the efficacy of tolvaptan, competitive vasopressin receptor 2 antagonist, for cirrhotic patients with reflactory ascites by using GWAS.
Others
Identification of genes affecting therapeutic effect of tolvaptan.
Exploratory
Pragmatic
Decrease of body weight.
Improvement of ascites.
Increase of urine volume.
Improvement of patient's symptom.
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
NO
NO
Institution is not considered as adjustment factor.
NO
No need to know
1
Treatment
Medicine |
Administration of tolvaptan (7.5mg/day) for a refractory ascites patients.
20 | years-old | <= |
Not applicable |
Male and Female
1)Patients over 20 years old
2)Patients obtained written informed consent
3) Life expectancy of at least 4 weeks
4) Adequate organ function
a) Hb>= 8.0g/dL
b) neutrophil: >= 1,500/mm3
c) Platelet: >= 30,000/mm3
d) Total bilirubin:< 4.0 mg/dL
e) ALT and AST: <= within 6 folds of normal limit
f) Serum creatine: <= 2.0 mg/dL
g) Serum natrium: >= 120mEq/L
1) Adequate cardiac organ function
a) Patients with conjestive heart failure above NYHA class3
b) Patients with severe hypertension
2) Patients with severe and active infectious disease (exclude HBV,HCV hepatitis)
3) Patients with HIV
4) Patients taking dialysis
5) Patients with portal tumor thrombosis (Vp3 or Vp4)
6) Patients with hepatic encephalopathy
7) Patients with crutial digestive bleedings within 4 weeks
8) Patients with the following treatment
a) Systemic chemotherapy
b) Being treated with invasive surgical therapy within 4 weeks
9) Patients with oral intake difficulty
10)Patients with severe digestive diseases
11)Patients taking a tablet which would affect this clinical study
12)Pregnant woman, lactating woman, or a woman suspected of pregnancy
13)Patients with severe allergic reaction to Tolvaptan
14)Patients with drug abuse or psycological disorders
15) Patients concluded to be inappropriate to participate in this study by their physitians
300
1st name | |
Middle name | |
Last name | Hideto Kawaratani |
Nara Medical University
The third department of internal medicine
Shijyo-cho 840, Kashihara, Nara, Japan
0744-22-3051(3415)
kawara@naramed-u.ac.jp
1st name | |
Middle name | |
Last name | Hideto Kawaratani |
Nara Medical University
The third department of internal medicine
Shijyo-cho 840, Kashihara, Nara, Japan
0744-22-3051(3415)
kawara@naramed-u.ac.jp
The third department of internal medicine, Nara Medical University
Nagoya city University
Local Government
Japan
NO
研究協力施設
2017 | Year | 02 | Month | 01 | Day |
Unpublished
Completed
2017 | Year | 02 | Month | 01 | Day |
2016 | Year | 12 | Month | 13 | Day |
2017 | Year | 02 | Month | 01 | Day |
2020 | Year | 03 | Month | 31 | Day |
2020 | Year | 03 | Month | 31 | Day |
2020 | Year | 03 | Month | 31 | Day |
2020 | Year | 12 | Month | 31 | Day |
2017 | Year | 01 | Month | 30 | Day |
2020 | Year | 02 | Month | 18 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000029337